Inflammation contributes to the development and perpetuation of several disorders 
Introduction
Several subsets of T and B-lymphocytes with highly specialized functions have been characterized so far. Some lymphocytes promote inflammation, whilst others have anti-inflammatory roles, and an optimal balance between these two opposing sets of lymphocytes is critical for immune homeostasis. We have recently characterized a pro-inflammatory subset of CD4 + T helper 1 (Th1) lymphocytes known as CD4 + CD28 null (CD28 null ) T cells as they characteristically lack CD28, a costimulatory receptor critical for the activation and function of T cells.
1, 2 CD4 + CD28 null T cells expand in several diseases that associate with chronic inflammation (e.g. autoimmunity, atherosclerosis, etc.), whilst in healthy individuals they are almost undetectable. 3 High frequencies of CD4 + CD28 null T cells correlate with disease severity and poor prognosis, which led to suggestions that these lymphocytes may be involved in the pathogenesis of chronic inflammatory disorders. 4 This review provides an overview on the 'signature' features that distinguish CD4 + CD28 null T cells from conventional CD4 + CD28 + T lymphocytes, the diseases in which these cells have been identified, the mechanisms that underlie expansion of this cell subset and potential therapeutic strategies that could be employed to target CD4 + CD28 null T cells.
The ABC of CD4 + CD28 null T cell biology
The main feature of CD4 + CD28 null T cells is the loss of CD28, a co-stimulatory receptor that is critical for the activation, proliferation and survival of CD4 + T cells. 5 For most CD4 + T cells and especially for naive CD4 + T lymphocytes, lack of CD28-transduced signals during activation induces an anergic state and renders lymphocytes unable to respond to antigen at subsequent encounters. 6 However, this is not the case with CD4 + CD28 null T cells that instead of being anergic have enhanced effector ! %! functions and can be (re)-stimulated by antigens. 7 Indeed, in several diseases in which this subset expands it has been shown that CD4 + CD28 null T cells have oligoclonal antigen receptors with restricted antigen diversity, suggesting that repeated antigen stimulation may facilitate expansion of these lymphocytes. 8, 9 Moreover, CD4 + CD28 null T lymphocytes display potent effector functions such as secretion of inflammatory cytokines interferon-! (IFN-!) and tumour necrosis factor-" (TNF-"). and potentially harmful T lymphocytes are purged through apoptosis, which ensures homeostasis and prevents a build-up of inflammatory T cells. Apoptosis induction is tightly regulated by the balance of pro-and anti-apoptotic signals induced in response to environmental queues. 54 Apoptotic cell death regularly proceeds either via the extrinsic (death-receptor-dependent) or intrinsic (mitochondrial-dependent) pathway, both of which culminate in activation of caspases that cleave DNA and other essential ! "#! cellular components, followed by the demise of the cell. 54 The extrinsic apoptosis pathway is initiated by ligation of death receptors such as Fas (CD95) that relay death signals through proteins that associate with their intracellular death domain. 55 The central molecules in the mitochondrial pathway belong to the Bcl-2 (B cell lymphoma-2) family, 56 which includes anti-apoptotic (e.g. Bcl-2, Bcl-xL) and proapoptotic proteins (e.g. Bim, Bax). 57, 58 One model proposes that anti-apoptotic Bcl-2 molecules form complexes with the pro-apoptotic Bax in the mitochondrial membrane, which prevents apoptosis induction unless these complexes are disintegrated. 57 This function is carried out by the pro-apoptotic molecule Bim, which in response to death triggers, displaces Bcl-2/Bcl-xL and releases Bax to exercise its death-inducing effects. 59 We 68 In a later study, the same group described that TNF-" blockade with
Infliximab induced a recovery of CD28 expression on peripheral blood mononuclear cells from RA patients. 69 Similar effects of Infliximab on CD28 expression were generated by treatment of whole blood from patients with unstable angina and elevated frequencies of CD4 + CD28 null T cells, which resulted in an increase in CD28 levels on T cells. 70 Based on these findings TNF-" blockade has been proposed to reduce the frequency of CD4 + CD28 null T cells in RA patients. However, a recent study found that the percentage of CD4 + CD28 null T cells remained unchanged in RA patients treated with Infliximab or Etanercept over a period of one year. 71 Interestingly, we have recently found that TNF-" treatment failed to down-regulate CD28 in primary CD4 + CD28 + T cells from both healthy individuals and patients with myocardial infarction (Bullenkamp J. and Dumitriu I.E., manuscript in preparation).
Moreover, due to severe adverse effects, use of TNF-" inhibitors is currently not justified in patients with myocardial infarction and the potential atheroprotective effects of TNF-" blockade remain to be precisely established in this disease. Another cytokine that has been proposed to enable CD28 re-expression is IL-12.
! "'! CD4 + CD28 null T cell clones re-stimulated in the presence of IL-12 were also shown to up-regulate CD28. 72 In contrast to TNF-", IL-12 on its own failed to up-regulate CD28. Whether IL-12 could induce CD28 re-expression in primary CD4 + CD28 null T cells is not known. Importantly, whether inflammatory cytokine blockade alters the function of CD4 + CD28 null T cells in addition to re-expression of CD28 has not been investigated.
Statins
In addition to their well-documented ability to down-regulate LDL-cholesterol, statins have anti-inflammatory and immune-modulatory effects. 73 Statin treatment in patients with unstable angina was suggested to reduce the percentage of CD4 + CD28 null T cells, although the effect was rather limited (from an average of 3% to 2.3%, p=0.022). T cell receptors (TCR) oligoclonal polyclonal 8, 9 Activating NK cell receptors (e.g. NKG2D) present absent 14 CX3CR1 (fractalkine receptor) present absent 36 'Signature' cytokines IFN-!, TNF-" variable # 1, 11 Cytolytic enzymes (perforin, granzymes) present absent 1, 12 Cytotoxic function present absent 1, 13 Resistance to apoptosis induction yes no 2, 60 Ability to provide help signals to B cells no yes 
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